Drug Discovery & Development
Microbial Genomics Oncology Genetic & Rare Disease Complex Disease Genomics Agrigenomics Cellular & Molecular Biology Research Population Genomics Pharmacogenomics Drug Discovery & Development Immunogenomics Neurogenomics Forensic Genomics Precision Health

Next-generation drug discovery powered by large-scale data and AI

Know more and discover faster with data insights and partnerships through Illumina BioInsight

Female scientist analyzing a monitor on a laptop in a lab setting; blurry image of a scientist in the background.

How large-scale data insights accelerate drug discovery

Drug development is one of the most complex and expensive undertakings in healthcare. Artificial intelligence (AI) is changing that by accelerating research, improving accuracy, and reducing costs, making it a game-changer for pharmaceutical industries and drug discovery.

2.6× higher approval rates with genetic evidence

2× higher patient selection rates with precision biomarkers

3.8× higher approval rates with gene targeting therapies

66% FDA-approved solutions were drugs supported by genetic evidence

22× higher chance of reaching clinical development for drug targets with integrated multiomics evidence

Front view of two female HCPs leaning on a standing desk, one is pointing to the monitor and the other is looking at the monitor; office supplies are on the desk next to another desktop and keyboard; blurry in the background is an easel with a hand-drawn chart.

Ready to accelerate your pipeline with Illumina data and AI?

Illumina provides world‑class genomic datasets, multiomic cohorts, and AI‑ready tools that support faster and more confident drug discovery. Whether your organization is looking to access existing data resources or create new multiomic assets, our team is ready to help.

BusinessDevelopment@illumina.com

Together we can solve the toughest challenges in drug discovery with Illumina BioInsight

Drug discovery is too complex for any single organization to tackle alone. Up to half of therapies fail before approval due to lack of clinical efficacy. Robust data and AI-driven analysis can help identify better targets earlier, reduce risk, and compress timelines.

To solve these hurdles, Illumina BioInsight brings together our expertise, multiomic data resources, and advanced analytical tools into a unified ecosystem so that you can turn scientific challenges into actionable insights with speed and reliability. By partnering with Illumina, you will gain access to data‑ready technologies, end‑to‑end workflows, and collaborative solutions built to advance modern drug discovery. Learn more below about how Illumina can support drug discovery through enhanced data analysis, reliable data sets, cost efficiency, and comprehensive workflows.

Smarter and faster drug development with AI-powered insights

AI thrives on data. Illumina provides access to massive, well‑designed, real‑world–linked multiomic data sets through collaborative partnerships to generate insights across the pipeline from early target discovery to clinical development. With Illumina advanced informatics and AI tools, teams can identify targets, understand mechanisms, predict outcomes, and optimize compounds faster and with greater confidence.

Greater accuracy and predictive power

Precision matters in drug development. Illumina sequencing technologies provide the depth and clarity needed to detect subtle genetic variations and complex biological patterns. This level of accuracy improves target validation, reduces false positives, and increases confidence in predictions to help researchers focus resources where they matter most.

Lower costs and higher efficiency

Every failed trial is costly. By integrating genomic insights early in the pipeline, we help reduce attrition rates and optimize trial design. With Illumina data solutions you will have fewer dead ends, better resource allocation, and a more efficient path to market, saving time and money without compromising quality.

Comprehensive solutions at every stage of development

Illumina provides an end‑to‑end foundation that supports your program as it evolves from exploratory research to late‑stage clinical work. Our integrated sequencing platforms, curated workflows, and scientific expertise help teams develop comprehensive solutions built to maximize success in drug discovery and advances for clinical development.

Illumina partnerships help your research and development pipelines

Illumina partnerships give you the advantage of world-class genomics expertise, advanced sequencing technologies, and integrated data solutions with AI-driven insights. By collaborating with Illumina, you gain access to tools and knowledge that accelerate discovery, reduce risk, and enable biology-informed decisions at every stage of your pipeline. From identifying novel targets to optimizing trial design, our partnerships help transform raw data into actionable intelligence. Together, we can shorten timelines, improve accuracy, and bring innovative therapies to patients faster.

Learn more about Illumina-enabled partnerships that are helping companies like AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, Novo Nordisk, Regeneron, and Alnylam make rapid, biology-informed progress in getting new solutions to market.

Allicance for Genomic Discovery (AGD)

See how the Alliance for Genomic Discovery (AGD) launched one of the largest, most comprehensive clinical genomic datasets of its kind with multiomic data to be added in next phase of its program.

The Billion Cell Atlas for AI‑driven drug discovery

Illumina is expanding the boundaries of drug discovery with the Billion Cell Atlas, a growing effort to map how genetic changes play out across billions of cells. In this press release, read more about how Illumina and our partners are using complex genomic data to impact new therapies.

Oviation.io GLP-1 dataset

Learn about the first real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies. This dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies.

Illumina partnerships help your research and development pipelines

Data cohorts

Access diverse, high-quality genomic datasets that power AI-driven insights. Our curated cohorts enable you to explore population-level trends, identify biomarkers, and validate targets with confidence. Whether you need rare disease data or large-scale population studies, we provide the foundation for precision drug development.

BusinessDevelopment@illumina.com

AI tools and expertise

Leverage advanced analytics and machine learning capabilities built for genomics. Our tools integrate seamlessly with your workflows, helping you uncover patterns, predict outcomes, and accelerate discovery. Backed by scientific expertise from Illumina you gain a partner in innovation for a new era in drug discovery.

Explore genomic AI tools

Custom services tailored to your pipeline

Our custom services adapt to your specific goals, from early discovery to clinical validation. Whether you need custom sequencing strategies, data interpretation, or secure data management, we deliver solutions designed to fit your timeline and objectives.

BusinessDevelopment@illumina.com

FAQ

Email BusinessDevelopment@illumina.com to start conversation about data access, pilot studies, or a collaboration agreement. You can also submit a request by filling out the form at the bottom of this page to speak to a specialist.

These resources can help you get started:

Illumina Billion Cell Atlas: Learn more about the scope, access options, and how the Illumina Billion Cell Atlas works with AI and target validation.

Alliance for Genomic Discovery: Read the milestone press release for dataset scale, access model, and early insights.

Ovation GLP‑1 multiomic data set: Learn about the first real-world data set with integrated multiomic insights from patients treated with GLP-1.

Yes. Illumina partners with biopharma to provide scientific consultation, co‑design custom cohorts, and generate multiomic data sets that can be linked to real-world clinical data. For more information, email BusinessDevelopment@illumina.com or use the form at the bottom to speak to a specialist.

Illumina has a track record of supporting over 90% of large national genomic initiatives and partnering with population‑scale genomics programs in more than 38 countries, giving teams access to broad, diverse datasets for discovery. In addition, Illumina end‑to‑end workflows deliver consistent, high‑quality results that reduce rework to accelerate insights. Our global support network and advanced analytical and AI‑enabled tools help researchers interpret multiomic data to make faster, more confident decisions with customizable analytical solutions.

/ Results

Is your drug pipeline ready for smarter decisions, better targets, and shorter timelines?

Partner with Illumina to co-create the future of therapeutic development. Contact our partnership team to join ongoing projects or discuss ways that we can enable your success.